P. 1
IPM- Final

IPM- Final

|Views: 216|Likes:
Published by Khanjan Kotecha

More info:

Published by: Khanjan Kotecha on Mar 22, 2011
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PPTX, PDF, TXT or read online from Scribd
See more
See less

05/25/2015

pdf

text

original

Indian Pharmaceutical Market An Overview

Total IPM & Incremental Value (in Rs. Cr.) YoY

Val. (Rs. Cr.)

IPM is growing at 19 . 6 %, which is the highest growth since 4 years , with a CAGR of 15 . 2 %

1

Growth Drivers of IPM
ü Macroeconomic Environment – Strong GDP growth, Rapid urbanization, Govt. initiatives, changing demographics & development of biologics. ü ü Healthy Environment – Increase private & govt. spending & increase access to lower class towns. ü ü Robust Market Trend – We observe that IPM is on a high growth trend for the 2 past year after a relatively low profile in

Chart 4- Growth Drivers Of the IPM
Fi u re s i () i d i te va l e g ro w th o f g n n ca u IPM i % n

% growth

3

166 32.719 6.841 4.7 Jun '10 MAT 43.630 4.365 2.823 4.Table 1: Performance of NI over the last 4 years Jun '07 MAT Jun '08 MAT Jun '09 MAT Value of IPM (`Cr.) No.183 6.2 Contribution to IPM (%) 7.285 2. Of NI Value of NI (Cr.810 2.562 2.856 4.6 36.5 4 .) 28.438 6.

Performance of NI over the last 4 years 5 .

1 81 . 4 6 .2% above Rs .Table 2 : No of NIs above Rs .3 Cr .5% 15 300 12. 10 Jun ’ 08 MAT Jun ’ 09 MAT Jun ’ 10 MAT 10 165 7. to total NI value Value of largest NIs ( Rs .) 30. 10 Cr . Contribution of NIs 6.3% 20 438 16 .9 52. 10 135 Cr . 10 Cr . of NIs above Rs . Jun ‘ 07 MAT No . 10 Cr . 1 % Value of NIs above Rs . 23.

08 2009 .9 20.12 (METFORMIN +SITAGLIPTIN) G03K1 MIFEPRISTON 2009 .9 81.1 20.-MIN. Brand Company Sub-group Prod.12 2009 .11 ( Rs.02 2009 .2 25.3 26. SOLID YYYY-MM 2008 . No.08 2008 .01 NOVARTIS A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN) MTPROST KIT CIPLA G03K1 MIFEPRISTON POLYBION SF* MERCK POLYBIONMERCK LC* NORFLOX-TZ* CIPLA JALRA USV A11E8 OTH.02 2008 .8 26. B-COMP.4 28.3 26.COMBINATION LIQIUDS A11E8 OTH.COMBINATION LIQIUDS P01A6 TINI+ OTH. Cr.Top 10 New Introductions as per ‘JUN 10 MAT S.5 27. COMBINATION SOLID A10BE OTHER ANTIDIABETICS-PLAIN (VILDAGLIPTIN) * REFORMULATIONS 7 .9 A10BT ANTIDAIBETICS COMBINATIONS2008 .) 2718.06 2009 . B-COMP. MULTIVIT.03 2008 .5 19. Launch Val IPM 1 2 3 4 5 6 7 8 9 10 AEROCORT* A TO Z NS* JANUMET MTP KIT GALVUS CIPLA ALKEM MSD CIPLA R03CK SALBUTAMOL + BECLOMETHASONE A11A4 OTH.

50 Cr. Demonstrating their success in brand building. ü Antidiabetics form the major therapy amongst new Introduction. within a year of launch. ü New Introduction by Cipla constituted to 51% amongst top ten Brands. ü 6/10 NI are combinations. thus indicating continued focus on combination drugs in India ü Mifepriston brands together account for Rs. ü Among the top 10 companies in IPM.Insights ü Among products that were launched New packs/ Reformulations showed the highest gain. only Cipla & Alkem are reflected in top 10 new introductions. thus indicating the huge potential of the contraceptive market 8 . indicating a strong potential in the segment.

Top 10 brands (Jun’ 10 MAT) Rank (G/L Brand over last year Company Value Incr.193 204 203 159 158 157 152 140 140 138 136 32 24 24 38 32 47 30 26 23 26 11 17 17 6 10 3 29 15 16 8 24 20 19 19 18 31 26 45 27 22 20 24 9 Human Mixtard 30/70 Abbott Revital Becosules Dexorange Zifi Monocef Ranbaxy Pfizer Franco Indian FDC Aristo Pharma . Cr.823 7. Value Value Growth % (Rs.) Jun' 09 Jun'10 MAT MAT IPM 1(1) 2(-1) 3(0) 4(3) 5(0) 6(7) 7(4) 8(1) 9(-1) 10(2) Corex Phensedyl Voveran Augmentin Pfizer Piramal Healthcare Novartis GSK 43. Cr.) (Rs.

10 .) & Phensedyl (203Cr.Cephalosporins.1 & 2 position respectively. No. are going neck to neck. ü üCorex (204Cr.INSIGHTS üCipla despite being the no. 1 company does not have a single brand in Top 10 products.). Acute therapy still has a strong foothold in the Top 10 brands. belong to the same class .Cefixime.used for Chronic Therapy. ü üZifi (FDC) & Monocef (Aristo). even after 30 years of its launch.9 & 10 brands respectively. ü üZifi with a value growth of 20% in Jun’ 10 MAT compared to 8% in Jun’09 MAT shows positive signs for Sub-class. ü üAugmentin (GSK) shows the 2nd highest incremental value of Rs. ü üExcept for Human Mixtard 30/70 (Abbott). both cough syrups occupying No.38Cr.

823 % contribution 60% 50% 40% 30% 20% 10% 0% Jun '07 MAT Jun '08 MAT Jun '09 MAT Jun '10 MAT MNC's 80 81 81 81 Indian Companies 11 . 630 19 43 . 856 19 36 .Contribution of Indian Companies & MNC’s to IPM 100% 90% 80% 70% 28 . 841 20 19 32 .

INSIGHTS üWith MNC’s looking out for Inorganic growth in IPM.g.(e. Abbott-Piramal) 12 . the figures are bound to improve for MNC’s in near future.

Vs MNCs 13 .Growth drivers of Indian Cos.

INDIAN COS . MNC 14 .

Top 10 companies in the IPM 15 .

3 0. 8. Cipla Ranbaxy GSK 2.8 -0.835 Healthcare Zydus Cadila 1.7 3.Top 10 companies in the IPM Rank (Jan’10 MAT) Companies Val (Rs.1 0.) Val growth (%) 1.413 1.625 Alkem Pfizer Mankind Abbott 1.1 365 273 295 288 319 345 258 245 340 239 19 15 19 19 24 27 22 22 35 24 Piramal 1. 2. 5.) MS (%) G/L in MS over Incr. 4.298 1.0 2. Cr.7 3.641 Sun Pharma 1.1 0.04 -0. 9. Cr.03 0.104 1.2 0.03 -0.872 5.3 4. 3.2 3.370 1. 6.1 3.3 4.8 4. value last year (Rs.2 3. 10.2 -0.1 0.243 16 .311 2. 7.

Growth Drivers of Top companies (3 5) (2 4) % Growth Figures in () indicate value growth of IPM in % 17 .

Company Turnover & Growth Grid
Value Growth (%) High >20% Turnover > Rs. 250 Cr. Turnover Rs. 100 - Rs. 250 cr. Turnover Rs.60– Rs.100Cr. Elder Pharma, Mankind, Macleods, Hegde & Hegde, Geno, Meyer Troikaa Pharma, Tablets Intas, Sun Pharma, MSD, Unichem, Organics, Win Medicare, Eli India, Baidyanath, East Zydus Cadila, Abbott, Sanofi Lilly, Allergan, Wanbury, India, UCB Pharma, TTK Aventis, Microlabs, USV, Alkem, Systopic, Orchid Chem & Healthcare Ltd. DRL, Franco Indian, Indoco, Pfizer, Pharma, Centaur, Blue Cross, Merck Ltd, Alembic, Glenmark, Hetero Healthcare Novartis 42% Cipla, GlaxoSmithKline, Piramal Healthcare, Ipca labs, Aristo Pharma, Lupin Ltd., Torrent Pharma, AstraZeneca, FDC, Ranbaxy, Wockhardt, Emcure, Cadila Pharma 4% Medley, Apex, Unique Pharma, Janssen Cilag, Jagson Pal, Wallace, Maneesh Pharma, Fourts India, Biochem, Raptakos Brett, Modi Mundi Pharma, Bestochem, Ajanta Pharma, Charak Pharma, Panacea Biotech, Albert David 6% Shreya Lifescience, CFL, Dabur, Ind-Swift 1% 1% Serum Institute, British Biological, Serdia, Walter Bushnell, Pharmed, Natco Pharma, Universal, Johnson & Johnson, Anglo French Drugs

Val. Contri.(%) to IPM Medium 10-20%

Val. Contri.(%) to IPM Low <10% Val. Contri.(%) to IPM

34% Himalaya Drug 1%

2% Biological E, Bayer Pharma Ltd., Dey S, Paras, RPG Life Sciences 1%

C o m p a n i s th a t h a ve m o ve d u p th e g ri , C o m p a n i s th a t h a ve m o ve d d o w n th e g ri , e d e d N e w co m p a n i s th a t h a ve e n te re d th e g ri , Companies that have remained in the same grid e d

18

ACUTE SEGMENT GROWTH DRIVERS

% growth

Figures in () indicate value growth of IPM in %
19

CHRONIC SEGMENT GROWTH DRIVERS
(23) (20)

(14)

% growth

Figures in () indicate value growth of IPM in %
20

Table 7: Top 10 Therapy segments in the IPM 21 .

8 5.65 0. of NIs Val/NI CAGR* (Rs.9 8.6 5.3 5.Rank Therapy (G/L over last year) Val.6 0.5 5.Cr) 17 11.8 5.5 11.562 705 354 555 430 568 361 287 116 230 337 0.71 1.64 0.9 8.7 5.54 0.Cr) 17.47 0.8 5.6 7.9 8. % Val.5 11 9 14 11 11 10 8 14 15 13 15 20 16 21 20 20 19 21 20 29 22 19 4. Contri.95 0.4 10.9 8.3 10. Cr) (%) JUN’09 MAT JUN’10 MAT JUN’09 JUN’10 MAT MAT IPM 1 2 3 4 5 6 7 8(+2) 9 10(-2) Anti Infectives Cardiac Gastro Intestinal Respiratory Pain/Analgesics Vitamins/ Minerals/ Nutrients Gynaecology Anti Diabetic Neuro/CNS Derma 36.5 15 14 19 14 14 12 12 17 23 17 15 *Note: CAGR is drawn over a period of 4 years 22 . % No.7 5.7 7.51 0.823 (Rs.37 0. Gr.51 0.5 43.631 (Rs.

INSIGHTS 23 .

Chart 10: Growth drivers of Top 10 Therapy segments in the IPM 24 .

Chart10:Growth drivers of Top 10 Therapy segments in IPM (29) (20) (20) (20) (19) Figures in () indicate value growth of IPM in % 25 .

INSIGHTS 26 .

27 .

Cr.) Portfolio (%) 4. 28 .6 6.Top 5 companies in the Anti-infectives Therapy Market Fi u re s i ( ) i d i te ra n k a s p e r Ju n ‘ 0 9 M A T g n n ca Company Val.) Share (%) Val. (Rs.772 64 AUGMENTIN 158 650 571 422 316 391 85 80 84 68 94 MOX TAXIM MONOCEF NOVAMOX 126 133 136 85 GLAXOSMITHKLINE (5) 416 AUGMENTIN 158 •Augmentin (GSK) being the top brand in the Anti-infectives segment. Cr.6 16 13 15 22 19 23 160 16 15 7 10 6 Value Contri.7 6. Mkt. (%) Brands > Rs. No.467 760 715 503 464 100 10.) Anti-infectives RANBAXY (1) ALKEM (2) ARISTO PHARMA (3) CIPLA (4) 7. Cr.1 position. Gr. To (Rs.2 9. •Value growth of GSK has been the highest at 23%. 10 Cr. Top Brand Value of Top Brand (Rs. Ranbaxy still holds No.2 5.

4 6 7 -n ve .Value (Rs. C r. Cr.)of Top 5 Companies in the Anti-infectives Therapy Market R a n k a s p e r Ju n ‘ 0 9 M A T A n ti i fe cti s V a l ( R s.) = 7 . Fi u re s i ( ) i d i te M a rke t S h a re (% ) g n n ca 29 .

30 .

5 Val Gr. Cr) Share (%) 5006 329 317 301 286 275 100 6. Cr) Portfolio (%) 123 2769 11 213 9 6 6 6 191 212 181 147 55 65 60 70 63 53 STORVAS AZTOR DILZEM ATEN LOSAR-H CARDIAC Sun Pharma (2) Torrent Pharma (1) Zydus Cadila (3) Unichem (6) Cipla (4) Value of Top Brand (Rs. Value Contri to (Rs.0 5.7 5.3 6. Cr) 97 39 47 82 63 AMLOPRES 44 31 . (%) 21 27 18 22 28 17 Brands > Rs. 10 Cr Top Brand No.Top 5 Companies in the Cardiac Therapy Market Figures in ( ) indicate rank as per Jun ’09 MAT Company Val Mrkt (Rs.6 6.

with a bigger product basket (11 Brands) leads the market.Insights 0 Storvas is the top brand in Cardiac segment but 0 0 0 0 0 Ranbaxy does not feature in top 5 companies. Aten and Amlopres featuring in top 5 brands. is indicative of good anti anginal therapy market. Unichem has shown a high growth rate and has moved up to number 4. Sun Pharma. With Dilzem. Storvas and Aztor both are among the top brands thus indicating good acceptance of dyslipidaemics in the market. The top 3 companies have managed to remain in the top positions since last year. 32 0 .

33 .

to (Rs. Cr.6 4.5 4.) 99 92 52 92 59 28 Gastro Intestinal ABBOTT (1) ZYDUS CADILA (2) DRL (3) ALKEM (5) MANKIND (6) 4771 291 265 231 213 198 100 6.) Share (%) Value Growth (%) No.8 4. Cr. Brands>10 Cr Value Contri. Cr.) portfolio (%) 103 9 7 6 5 3 2687 265 194 193 158 62 56 91 73 84 74 31 Zinetac Digene Ocid Omez Pan Zenflox-OZ Top Brand Value of Top Brand (Rs.1 20 18 24 23 38 29 34 .1 5.To p 5 co m p a n i s i th e G a stro I te sti a lT h e ra p y e n n n M a rke t Fi u re s i ( ) i d i te ra n k a s p e r Ju n ’ 0 9 M A T g n n ca Company Value Mkt (Rs.

Omez and Pan are among the top brand thus indicating good acceptance of PPI in the market. 0 Abbott has 91% brands above 10 crores.Insights 0 Zinetac is the top brand in GI segment but GSK does not feature in top 5 0 Mankind with just 3 brands greater than 10 crores has made it top 5 0 Ocid. possibly the reason why it is placed at the top in GI category 0 The top 3 companies have managed to maintain their positions since last year 0 Alkem has shown a high growth rate and has moved up a spot to number 4 0 35 .

36 .

) Share Growth (%) (%) No .) Respirat 3895 ory Cipla 715 Piramal Pfizer Zydus Cadila GSK 311 249 173 168 100 18. Cr ) Contributi on to portfolio ( %) Top Brand Value of top brand (Rs.4 4.Table 11 : Top 5 Companies in Respiratory Therapy Market Company Value Mkt Val.4 4.3 20 16 15 23 23 9 72 13 4 2 3 6 2258 553 277 223 102 115 58 77 89 89 59 69 Corex Asthalin 204 126 Phenesedyl 203 Cough Corex 204 Deriphylli 62 ne Cetzine 41 37 . Cr.4 8 6. Value ( Rs . Brands > Rs10 cr (Rs cr.

INSIGHTS 0 Companies having a Value growth of more than 20 % are the growth drivers of respiratory segment. • 0 Pfizer and Piramal Healthcare are highly vulnerable because of their high dependence on one brand in their portfolio (89%) • 0 Top 5 companies in Respiratory segment contribute to 40% of market. • 0 Pfizer and Zydus Cadila are the growth drivers among top 5 companies. • 38 .

39 .

7 20 10 393 89 Human Mixtard 30/70 157 USV (2) 272 10.Top 5 companies in the Anti .) portfolio (%) 1614 65 Human Mixtard 30/70 157 Valueof Top Brand (Rs.) 2500 Market Growth No.5 30 31 28 23 9 5 6 3 231 184 138 85 85 93 79 76 Glycomet Lantus Glucored Huminsulin 30/70 66 68 45 63 Sanofi Aventis (3) 199 Sun Pharma (4) Eli Lilly (5) 175 113 40 . Cr. To (Rs.9 7 4.9 7. Cr. Cr. 10 croreTop brand Anti Diabetic Value Contri.) Abbott (1) 442 17.diabetic Therapy Market Figures in ( ) indicate rank as per Jun ’09 MAT Company Value (Rs. Share (%) (%) 100 29 63 Brands > Rs.

41 .

TOP COMPANIES IN EACH ZONES RANK 1 2 3 4 5 6 7 8 9 10 IPM CIPLA RANBAXY GSK PIRAMAL ZYDUS SUN ALKEM PFIZER MANKIND (2) ABBOTT NORTH CIPLA RANBAXY PIRAMAL GSK MANKIND ZYDUS LUPIN PFIZER ALKEM (2) SUN EAST ALKEM GSK PIRAMAL (1) RANBAXY(-1) SUN ZYDUS (1) CIPLA (-1) ALEMBIC (2) ARISTO PFIZER (-2) WEST CIPLA PIRAMAL (1) ZYDUS (2) GSK (-2) PFIZER (2) RANBAXY (-2) EMCURE (-1) SUN (1) FDC (-1) MANKIND (3) SOUTH RANBAXY CIPLA SUN GSK ZYDUS ABBOTT (1) PIRAMAL (-1) DRL (1) MICROLABS (-1) PFIZER 42 .

and are not in top ten in other markets. 0 0 0 0 43 . and Piramal in south 0 Companies such as Microlabs and Dr Reddy’s laboratories have a grip on south market only.INSIGHTS 0 Market leader Cipla is doing well in most markets except east 0 Similarly Ranbaxy is doing well in most markets except west.

44 .

Top 10 companies across Companies Rank Metro 1 2 3 4 5 6 7 8 9 10 Ranbaxy Cipla Sun Pharma Zydus Cadila Pfizer GSK Piramal Healthcare Sanofi Aventis Abbott Lupin Class I Cipla Ranbaxy Class II-VI Rural Cipla Cipla Piramal HealthcarePiramal Healthcare GSK Mankind Ranbaxy Alkem Zydus Cadila Aristo Pharma Pfizer Abbott GSK GSK Piramal HealthcareRanbaxy Zydus Cadila Sun Pharma Alkem Lupin Pfizer Abbott Mankind Alkem Zydus Cadila Sun Pharma Aristo Pharma Pfizer qGSK has a stronger hold in Class I-IV & Rural areas than in Metro qPfizer & Abbott trying to penetrate the class I-IV & Rural market qGrowing presence of MNCs can be seen in rural areas 45 .

46 .

Contribution of SSA and HSA in the IPM Figures in ( ) are value growth % 47 .

Hospital Segment Performance 0 Hospital segment has registered a robust value growth of 37% (Jun 10 MAT) as compared to last year’s 21% (Jun 09 MAT). which supports the fact that Hospital sector is gaining importance in the IPM and as a result more players are strengthening their focus towards this sector. growth of 37% growth as per Jun’10 MAT 48 0 0 In terms of growth. 0 0 Hospital segment contributed 9% to the total IPM 0 0 The trend for past 4 years showed an upward trend in this contribution from Jun’07 MAT to Jun’10 MAT. Hospital sales showed high • . (SSA + HAS) as per Jun’10 MAT.

Cr. ( %) 37 35 60 44 39 57 44 48 46 39 16 49 .) IPM 4.Top Companies in Hospital Market HSA rank Jun ‘10 MAT (HSA rank Jun ‘07 MAT) Company 1 (1) 2 (6) 3 (2) 4 (5) 5 (3) 6 (9) 7 (4) 8 (8) 9 (10) 10 (7) Value ( Rs.313 GlaxoSmithKline 251 Sun Pharma 240 Cipla 228 Zydus Cadila 189 Pfizer 189 Piramal Healthcare 180 Sanofi Aventis 178 Ranbaxy 165 Lupin Limited 156 Alkem 137 Val Gr.

Sanofi Aventis and Alkem has the greatest had the greatest change in the ranking. 50 .Insights 0 There is a considerable shift in the ranks of companies in the hospital segment 0 Sun pharma.

2% 5.0% 4.Top therapies in hospital market Rank (G/L) over last year) 1 2 3 4 5 6 7(+1) 8 (-1) 9 10 Therapy Value contribution(%) June ‘09 MAT 3155 Crs 26.1% Value growth (%) June ‘09 MAT 21 18 19 21 21 26 38 29 18 11 21 June ‘10 MAT 37 30 45 34 33 34 30 49 32 57 58 CAGR (%) IPM Anti infectives Cardiac Gastro intestinal Pain/Analgesics Gynaec Respiratory Neuro/CNS 23 20 25 19 22 21 29 31 18 31 35 51 Vitamins/Minerals 5.3% Anti diabetic 3.0% June ‘10 MAT 4313 Crs 25.4% 6.9% 5.6% 5.3% 7.0% 5.6% 11.8% 8.11% 8.1% 7.9% 5.1% /Nutrients Others 4.5% .8% 11.9% 4.4% 5.

52 .e. 0 Neuro and CNS increased the contribution by 0.Insights 0 All the top 10 therapies have recorded a robust double digit growth i. more than 30% growth.4% 0 New introductions added an incremental value of Rs. which constitutes 26% of the total incremental value. 300 Cr.

6% Super 31.2% 40.Specialty – wise prescription split Specialty Rx contribution% Jun ‘ 09 MAT Jun ‘10 MAT All Specialties 156 crs 164 crs General 40.1% practitioners Mass specialties 28.3% specialties 53 .6 % 28.1% 31.

In Jun’10 general practitioners added more number of prescriptions (3.1cr). 54 .Highest Rx contribution was obtained from general practitioners .

Top therapies in IPM Therapies Total Anti infective Cardiac Gastro intestinal Respiratory Pain/analgesics Vitamins / Minerals / Nutrients Gynecology Anti Diabetic Neuro / CNS Derma Rx contribution % Total G. l specialtie specialties 164 40% 31% 29% Cr.Tota Super Mass Rx (Rs.P.) s 63 50% 24% 26% 9 20% 42% 38% 51 43% 26% 31% 37 49% 18% 33% 61 40% 36% 25% 30 38% 28% 35% 11 30% 12% 58% 4 14% 42% 44% 11 21% 53% 27% 9 34% 36% 30% 55 .

anti infective therapy is the 56 .Currently .

highest prescription contribution: Anti infective therapy Super specialties highest prescription contribution: neuro/CNS therapy Mass specialties highest prescription contribution: Gynaecology 57 .GPs .

9% 5.1% 8.6% 5.3% 4.6% 4. 10.1% 6.8% 10.2% 8.7% 6.7% Jun '10 MAT 164 Cr . in IMS Rx Audit Figures in ( ) are value growth % Rank   1 (1) 2 (2) 3 (4) 4 (3) 5 (5) 6 (6) 7 (7) 8 (8) 9 (9) Companies IPM GSK Cipla Mankind Piramal Healthcare Zydus Cadila Ranbaxy DRL FDC Alkem Rx contribution (%) Jun '09 MAT 156 Cr .1% 8.8% 7.1% 7.9% 7. 10.0% 6.9% 9.7% 9.6% 6.9% 58 10 (11) Sun Pharma .1% 5.Top co.

3% of total IPM (Jun ‘10 MAT) 0 The total contribution of Rx to IPM is low. Indicating a heavy trend of OTX. in Prescription Audit Insights 0 Rx IPM contributes to 0. Indicating good acceptance among doctors. 0 GSK is the only MNC that features among the top 10 (Assumption: Piramal & Ranbaxy started as Indian and later acquired by MNC) 0 59 . 0 GSK & Cipla have managed to be doctor’s favorite while prescribing.Top co. 0 Mankind has grown by leaps and bound each year even in Rx market.

Prescription & Prescriber Dispersion June '10 MAT Rx contri (%) Total 164 Cr. GP (Non MBBS) 65% GP (MBBS) 35% MASS SPECIALITIES 47 Cr. GP Total 66 Cr. Dentist 29% Orthopaedic 12% Opthamologist 9% ENT Specialist 8% Cardiologist 6% Dermatologist 6% Chest TB Specialist 4% Neurologist Neuro Surgeon 3% Nephrologist Urologist 3% Diabetologist Endocrinologist 3% Psychiatrist 3% Gastroenterologist 3% Oncologist 1% Rxber contribution (%) 244000 94000 69% 32% 65000 34% 28% 23% 16% 85000 33% 12% 11% 8% 7% 6% 5% 5% 4% 3% 3% 3% 2% 60 . Gynaecologist 27% CP 30% Paediatrician 28% Gen. Surgeon 14% SUPER SPECIALITIES 51 Cr.

0Top 3 Rxber contribution (1) GP (Non-MBBS) (2) Gynaecs (3) Dentists 0Barring dentists the overall superspeciality size is comparitively smaller. 0 61 . prescribers are GP (Non MBBS) – Might indicate patients price sensivity towards Doctor’s fees.Prescription & Prescriber Dispersion Insights 0Max.

Indian Vaccine Market .An Overview 62 .

Cr.2% Total IPM & Incremental Value (in Rs. (Rs.15. Cr.) Source: IMS – June’10 MAT 63 .Indian Pharmaceutical Market .highest since 4 years.6% Gr .An Overview 19. CAGR.) YoY Val.

Cr.Vaccine Market . (Rs.Trend Growth double than last year (53) Val.) (24) (>>) (-2) June MAT Source: IMS – June’10 MAT Fig ( ):% Val Gr 64 .

Vaccine Market: Business Channels (53) (48) (41) Dispensing doctors & Hospitals drive m (-27) (96) (>>) (10) (19) Source: IMS – June’10 MAT Fig ( ):% Val Gr 65 .

MNCs drive market Vaccine Market:Indian Vs MNCs (21) (38) (27) (64) Source: IMS – June’10 MAT Fig ( ):% Val Gr 66 .

Cr. (Rs. Growth % % 100% 53 18% 23 18% >> 10% 75 9% -12 9% 40 8% 57 5% >> 4% 56 4% >> 3% 15 67 .Vaccine Market: Rank June’10 MAT 1 2 3 4 5 6 7 8 9 10 Company Vaccine Market GSK Sanofi Aventis Pfizer Novartis Serum Institute Panacea Biotech VHB Lifesciences Zydus Cadila MSD Shantha Biotech Top 10 Companies Top 10 contributes 90 % Val.) 726 131 129 71 68 68 59 33 32 31 24 Market Share Val.

1 Market 211 Toddler Vaccine 205 Adult Vaccine 146 Paediatric Combinati131 Paediatric on Other 33 Single All Vaccines Vaccines Val. June’0 June’10 Cr. (Rs. Grwth % Incr.) June’09 June’10 9 MAT MAT MAT MAT 24 53 93 250 55 60 47 79 -4 22 -7 37 67 >> 28 77 25 32 20 32 --431 6 27 68 .) 726. Val. Vaccine Cr.Vaccine Market :Top Therapies Share % 100% 29% 28% 20% 18% 5% Therapie Value s (Rs.

50 % Incr. Cr. val.1 24 3 7 2 5 -3 -1 5 0 10 250 30 -9 39 12 18 11 -2 16 21 11 69 Vaccine Market 1 2 3 4 5 6 7 8) 9 10 Prevenar Rabipur Pentaxim Havrix Varivax Vaxirab Varil Rix Gardasil Verorab Rotarix Pfizer Novartis 726 71 68 24 150 4 >> 9 59 -11 -3 ---------- Sanofi Aventis 46 GSK VHB Zydus Cadila GSK MSD 37 33 32 25 22 Sanofi Aventis 21 GSK 21 .) June’09 June’10 Mat MAT 93. (Rs.) Top 10 Brands Val. Cr. Growth % June’09 Mat June’10 MAT 53 75 -12 >> 47 >> 56 -9 >> --->> Top 10 contributes -. (Rs.Rank Brands June’10 MAT Vaccine Market: Company Val.

) Val. 104 79 Cr. 55 % contr .) 22 16 21 11 16 12 11 10 9 6 7 7 4 3 3 3 2 2 2 1 70 .SD Serum Institute Shan HIB. (Rs. (Rs.Vaccine Market : Top 10 NIS NIs Comapny Launch Date YYYY MM 10 2008 2008 07 2008 10 2009 02 2008 07 2009 10 2008 11 2009 02 2009 11 2008 09 NIs 7 . Cr. Vaccine Market Gardasil MSD Rotarix GSK Pentavac Serum Institute Cervarix GSK Polprotec Panacea Biotech Xprab RANBAXY Quadrovax Serum Institute Comvac.DPTShantha Biotech Value Incr.5 Bharat Biotech Pentavac .

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->